Journal
BLOOD
Volume 134, Issue 13, Pages 996-998Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2019002237
Keywords
-
Categories
Ask authors/readers for more resources
In this issue of Blood, Goy et al report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed nongerminal center diffuse large B-cell lymphoma (DLBCL).(1)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
